The aim of this study was to assess the haemodynamic effects of tri-iodothyronine (T3) and methylprednisolone in potential heart donors.
Introduction
Brainstem death (BSD) produces haemodynamic, hormonal, inflammatory, and biochemical changes that may contribute to a decline in cardiac function. 1 As the demand for donor hearts exceeds supply, there is a need to maximize the retrieval rate from the existing donor pool. Following BSD, there is commonly a decline in circulating cortisol, insulin, and thyroxine (T4). Tri-iodothyronine (T3) may also be reduced, sometimes with normal T4, low thyroid-stimulating hormone (TSH) and elevated reverse T3 constituting a 'sick euthyroid' syndrome. 3 -6 These phenomena led to the use of hormonal replacement therapy (HRT) in potential heart donors. Retrospective studies suggest that HRT comprising steroid, thyroid hormone, and vasopressin (VP) enhances retrieval rate with improved post-transplant function. 7, 8 However, while the control of post-BSD vasoparesis using VP is well established, 9 the role of T3 and steroids is less clear. Some studies report a haemodynamic improvement following T3 administration, whereas others suggest T3 to be either of no benefit or detrimental. 10 -13 Steroids that have a membrane-stabilizing effect and inhibit the elaboration of cytokines 14 may be beneficial in the pro-inflammatory post-BSD environment, particularly in lung transplantation, 15 but an effect on haemodynamic function has not been examined. We therefore investigated the individual or combined effects of methylprednisolone (MP) and T3 on donor heart function in potential donors in a randomized double-blind factorially designed trial.
Methods

Study design
In the UK, transplant centres are responsible for heart retrieval within a specified zone. Between January 2004 and April 2006, the next-of-kin of eligible potential heart donors [age !16 to 65 years, confirmed permission for heart donation, no history of ischaemic heart disease, or major thoracic trauma, in an intensive care unit (ICU) within 2 h road distance of our recipient centre] were approached for consent to enter the donor into a prospective, double-blind, placebocontrolled, factorially designed randomized trial. The research was supported by 33 accessible ICUs and approved by a multi-centre research Ethics Committee, all UK cardiothoracic transplant centres, and all zonal liver and kidney retrieval teams. The trial was conducted independently of whether donor hearts were provisionally accepted for transplantation by any centre. Hearts that were not provisionally accepted were not re-offered following management. Consent was obtained from the next-of-kin for all participating donors according to the ethical approval.
Initial assessment and management
As soon as possible following consent to both donation and the study, donors were attended by a donor research fellow who drew blood for thyroid function assessment and inserted a pulmonary artery flotation catheter (PAFC; VoLEF catheter, Pulsion Medical UK Ltd) and femoral arterial thermodilution catheter (PiCCO, Pulsion Medical UK Ltd). Following measurement of central venous pressure (CVP), mean arterial pressure (MAP), pulmonary capillary wedge pressure (PCWP), cardiac index (CI), right and left ventricular stroke work index (RVSWI and LVSWI), right ventricular ejection fraction, cardiac power output (CPO), systemic vascular resistance (SVR), the study medication was administered. Donors were randomly assigned to receive T3 (0.8 mg kg 21 i.v. bolus followed by 0.113 mg kg 21 h 21 i.v. infusion);
and MP (1000 mg as a single i.v. bolus), both drugs or placebo (dextrose 5%) on 1:1:1:1 basis using a computerized model with permuted blocks and a sealed envelope system. The T3 dose was based on reports of positive haemodynamic effect following cardiac surgery. 16, 17 The T3 or placebo infusion continued until retrieval. 
Endpoints and statistics
The primary endpoint of the study was the difference in CI between groups at end-assessment. . Normally distributed variables were tested using two-way ANOVA that included factors for the two treatments given and also their interaction. The post-treatment variables were tested using ANCOVA using the pre-treatment value as a covariate along with the two treatments given and their interaction. The interaction between treatments was not significant and so the P-values for the main effects are reported for the model without interaction. The impact of donor management was analysed on the entire cohort of patients using the paired sample t-test. Skewed data were tested using non-parametric tests (MannWhitney and Kruskal -Wallis test). Categorical data were analysed using x 2 and Fisher's exact tests. Serial measurements of CIs were compared with repeated measures ANOVA. We included a withinsubjects factor with five levels for the five repeated measurements of CI (primary outcome measure of the study) and the two treatments were entered as between-subjects factors. We used a full factorial model with type III partitioning of the sums of squares and the P-values quoted are those obtained after applying the Huynh -Feldt correction. The interaction of the within-subjects factor and each treatment was used to assess whether the treatment had any effect on change in CI. No interaction between treatments was identified and the P-values for the main effects are reported for the model without interaction. Statistical significance was assigned when P 0.05 and all tests were two-sided.
Results
During the period of recruitment, of 250 zonal donors, 116 were eligible for study. Consent was withheld in 36 giving a sample size of 80 ( Figure 1 ). The donor characteristics of both trial (80) and the non-trial donors (134) are presented in Table 1 . The median age was 43 (IQR 36 -55), 52% were male, and 11 (14%), 1 (1.25%), and 32 (40%), respectively, had a history of hypertension, diabetes, or smoking. Brainstem death was caused by trauma in 19/80 (24%), vascular event or tumour in 51/80 (64%), and hypoxia or infection in 10/80 (13%). Assessment commenced within a median of 2 (IQR 0.5 -3.5) h of consent, within 12.7 + 8.3 h of coning, and 6.9 + 1.3 h prior to retrieval or end-assessment. Study medication was administered for 5.9 + 1.3 h prior to retrieval or end-assessment; the T3 or placebo infusion being continued until OR inspection. Between initial and final measurements, donors received 346 + 344 mL of colloid raising CVP and PCWP significantly ( Table 2 ). In the study population overall, CI, CPO, RVSWI, and LVSWI all increased (P , 0.001), whereas SVR fell.
Donor heart function within the four treatment groups of the trial
Demographic details, donor heart function, and suitability for transplantation for the four treatment groups are summarized in Data presented as median (25th, 75th centiles) and mean + SD. Post-treatment values were presented with a prefix-P. Units as per Table 2 . P-values for T3 and methylprednisolone (MP) were generated from ANCOVA analysis for the two main treatment effects after removal of the T3 þ MP interaction from the model.
administration of T3 and MP alone or in combination did not affect CI ( Figure 2) or any other parameter when compared with placebo.
Donor heart function according to receipt of T3 or MP
In a secondary analysis, we compared outcomes in donors according to receipt of T3 (i.e. T3 group plus T3 þ MP group) or MP (MP group plus T3 þ MP group) (Tables 4 and 5). Tri-iodothyronine administration was not associated with any identifiable beneficial haemodynamic effect (Figure 3) . The receipt of MP did not influence circulatory functional changes or retrieval rate ( Figure 4 ).
Donor heart function according to pre-treatment thyroid function
We further examined the effect of T3 therapy according to the pre-treatment thyroid hormone levels ( Table 6 ). Over half the donors (46/80; 58%) had low free T3 or free T4 levels initially, whereas only 18 had coexistent low TSH levels. Of the 46 donors with low T3 or T4 levels, 24 received T3, thereby achieving supra-physiological T3 levels. In donors not receiving T3, free T3 levels fell significantly (P , 0.001). We compared the changes in CI according to initial T3/T4 levels and T3 receipt. Initial CI was not different in donors with low T3 or T4 levels. The management protocol improved CI regardless of initial T3/T4 levels or T3 administration ( Figure 5 ).
Donor heart function and norepinephrine administration
Within our data, we noted an apparent association between NE withdrawal and cardiac functional improvement and performed a further post hoc analysis. At assessment, 7 donors were on Data presented as median (25th, 75th centiles) and mean + SD (95% confidence limits). Post-treatment values were presented with a prefix-P. Units as per Table 2 . The P-values are as for Table 3 and were generated from ANCOVA analysis for two main treatment effects after the non-significant T3 þ MP interaction was removed from the model. in donors receiving or not receiving T3 (n ¼ 40 in each group). The x-axis denotes time in hours following initial assessment after which T3 or placebo was administered. Note that the interval between the third hour and end-assessment was 1 -2 h. Both groups improved CI significantly (P , 0.001) between baseline and end-assessment. On repeated measure ANOVA analysis, no significant difference was noted between the groups (T3, P ¼ 0.17; MP, P ¼ 0.9; T3 þ MP, P ¼ 0.252; T3 and time, P ¼ 0.56; MP and time, P ¼ 0.47; T3 þ MP and time, P ¼ 0.86). Marginal and non-marginal donor hearts, transplant suitability, and outcomes
At initial assessment, half of the donor hearts met the functional criteria of suitability for transplantation. Of these, 26/40 remained suitable at the end-assessment and 15/26 hearts were transplanted. The reasons for rejection or non-use are detailed in Figure 6 . Of 40/80 of the donor hearts with initial marginal status, 14/40 (35%) attained the functional suitability criteria at end-assessment and 10 (25%) were transplanted with no recipient 30-day mortality. Administration of T3 and MP alone or in combination did not influence the haemodynamic parameters or transplant rate. Twenty donors [25%; median age 55 (range 48 -57)] had palpable CAD on direct inspection, despite a negative medical history, and 7/20 donors with CAD also had LVH. At end-assessment, 20 further hearts were deemed unsuitable for transplant on the basis of inadequate function or macroscopic right (n ¼ 11) or left (n ¼ 9) heart dysfunction. Thus, from 80 potential donors assessed, 40 hearts (50%) were ultimately suitable for transplant and 25 (31%) were actually transplanted. As 15 additional hearts, not provisionally accepted for transplantation, fulfilled the suitability criteria, the actual percentage of potentially usable hearts was 50%. Of these 15, 5 had been rejected for reasons of donor age !60 (n ¼ 3), history of hypotension (n ¼ 1), or inotrope use (n ¼ 1) and 10 were rejected due to an inability to identify suitable recipients. They were not re-offered at endmanagement. Following transplantation, 24/25 recipients survived beyond 30-day (96%) and 1-year survival was 88%. The early death was unrelated to graft function.
Discussion
Active donor management improves circulatory function and has the capacity to increase the yield of suitable hearts from the existing pool of potential donors. Neither T3 nor MP, alone or in combination, appears fundamental to this improvement.
The clinical relevance and management of post-BSD thyroid dysfunction remains an area of controversy. 1,3,20 -23 In experimental studies of BSD, rapid falls of T3 have been documented. This led to supplementation of T3 in the human donor with salutary results compared with historical controls. Observational studies with limited haemodynamic assessment then showed a general beneficial effect of T3. 10, 24 In a report of six dysfunctional donor hearts (mean age 16.5 years) with high CVP, left ventricular ejection fraction , 45%, inotrope requirement, and episodes of cardiac arrest, T3 administration was followed by an increase in MAP, a fall in filling pressures, and successful transplantation. 11 However, the donors also received furosemide and dopamine which may have been responsible for the fall in pre-load and increased MAP. 11, 25 Thereafter, T3 was used in management regimes that incorporated PAFC-guided manipulation of pre-load, afterload, and inotropy. 19 These measures led to improved cardiovascular performance and increased donation rates but as HRT was administered to all, a specific beneficial effect of T3 could not be evaluated. T4 therapy has also been reported to reduce catecholamine requirements but does not change cardiac output and actually increases oxygen consumption and base deficit. 25 In our study and previous randomized studies, low T3 levels were not associated with worse haemodynamics and T3 administration did not affect retrieval rate or haemodynamics beyond that achieved by the other components of management. 12, 13, 27 This suggests that T3 reduction is not the mechanism of donor circulatory dysfunction. Low T3 levels were found in .50% of donors in the current study and all T3 recipients achieved T3 levels above the upper reference limit. The change in CI was not different regardless of initial T3/T4 levels or T3 administration. Additionally, T3 donors received the drug for a longer period than reported previously and our weight-based nomogram provided slightly higher dosages that have previously been shown to improve post-coronary artery bypass surgery haemodynamics without increasing oxygen consumption. 17 The reasons for these discrepant findings are unclear. T3 has been found to ameliorate post-ischaemic cardiac dysfunction, 16, 17 to improve contractile performance after excessive catecholamine stimulation, 16, 17, 28 and to stabilize pressor requirements following brain death. 29, 30 We suspect that the reasons relate to vascular resistance modulation with VP. Vasopressin levels fall profoundly following BSD 29, 31 in parallel with the progressive vasoparesis. Administration of VP reverses this phenomenon, stabilizing blood pressure and reducing catecholamine requirements as in this study. 31 -33 Vasopressin administration, which was not used in the early observational studies that suggested improvement with T3, therefore appears to have a more fundamental role in donor management than T3.
In a large retrospective survey, HRT was associated with an increased retrieval rate of the heart and other organs. However, only 701/10 292 (6.8%) donors received HRT and only 47/701 (,0.5%) received T3. The remainder received T4 which may be preferentially converted to the inactive r-T3 in the 'sick euthyroid' state and be thereby clinically ineffective. Donors receiving HRT were significantly younger and less likely to have died from cerebrovascular accidents or have diabetes, hypertension, or renal dysfunction; factors predictive of a lower yield of hearts for transplantation. Moreover, although donors that received HRT had a statistically higher thoracic organ donation rate, this is intuitive as only donors under active consideration for heart donation may have been prescribed T3 or T4. 7 A second retrospective report from the same database suggested that triple HRT (i.e. T3 or T4, steroids, and VP) reduced recipient mortality and the incidence of early graft dysfunction. Duration of therapy was not reported but non-HRT hearts had longer ischaemic times and non-HRT recipients had a higher incidence of congenital heart disease, ventilator dependency, and female donor-to-male recipient matching; factors predictive of worse post-transplant outcome. Only a triple HRT combination was associated with a beneficial effect; the administration of T3 or T4 alone was not beneficial. Thus, the investigation of the individual roles of the hormonal agents remains relevant. Figure 6 Organization chart of donor heart outcomes within the study.
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The current study suggests that neither T3 nor a T3/MP combination lead to an additional improvement in donor circulatory function beyond that achieved by active management. Their routine use for this indication remains, therefore, an area of debate.
Norepinephrine is known to be cardiotoxic and a coronary vasoconstrictor. 34 NE accelerates cardiovascular decline in the vasoparetic phase that follows the catecholamine storm 35 and has been associated with reduced right ventricular contractility and worse heart recipient survival. 36, 37 This association between NE and reduced function was confirmed in the post hoc analyses in the current study and NE withdrawal and substitution with VP was associated with improved function, attributable at least in part to normalization of SVR and VP's lack of cardiotoxicity; a finding consistent with previous reports. 35, 38, 39 Despite these adverse effects, NE remains the most commonly used pressor agent in hypotensive organ donors. Our data support the view that the use of NE infusions for post-BSD pressor support should be abandoned and VP utilized in preference. In conjunction with invasive cardiac functional assessment, this allows manipulation of pre-load and afterload, and discrimination between those donor hearts that can be resuscitated from those that cannot. The sample size, although larger than previously reported, reflects the logistical difficulties of undertaking such prospective, randomized, blinded, and controlled studies in this population. It remains relatively numerically small and thereby under-powered to confidently exclude some positive haemodynamic effects of multi-hormone therapy, particularly in donors with initially low T3 or T4 levels or an advantageous post-ischaemic effect following recipient implantation. The randomization process permitted age differences to occur in the trial treatment groups but this does not, we believe, significantly alter the interpretation of the data. Although we have not reported recipient outcomes in detail, overall graft survival appears satisfactory regardless of HRT use. The donor age reported in this study reflects a typical change in the donor population observed worldwide. The incidence of CAD is of concern, particularly as coronary angiographic screening is not available in many countries and alternative methods of screening to rule out CAD in donors need to be identified.
Our study demonstrates that not only may donor circulatory status be improved by active management but also there is the potential to increase the yield of transplantable hearts if decisions on organ acceptance are deferred until a period of resuscitation and assessment is complete. Active donor management with PAFC monitoring is the cornerstone of this objective but this has implications for planning donor retrieval services. The simple introduction of hormone therapy is not a substitute for the detailed haemodynamic assessment and management of the potential heart donor.
